IDEAYA Biosciences Announces Participation in the 43rd Annual JP Morgan Healthcare Conference and Corporate Guidance for 2025 By Investing.com

SOUTH SAN FRANCISCO, California., January 12, 2025 /PRNewswire/ — IDEAYA Biosciences (NASDAQ:), Inc. (NASDAQ: IDYA), an oncology precision medicine company dedicated to the discovery and development of targeted therapies, announced its participation in the 43rd annual JP Morgan Healthcare Conference and provided corporate guidance and program updates for 2025.

43rd annual JP Morgan Healthcare Conference
Monday, January 13^th2025, in 17:15 PT (8:15 PM ET)

• Author’s presentation Yujiro S. Hatachief executive officer, IDEAS Biosciencesfollowed by a Q&A with analysts Anupam Ramageneral manager, US SMID Biotechnology Equity ResearchJP Morgan

The corporate guidelines for 2025 will be presented at the 43rd^rd Annual JP Morgan Healthcare Conference:

• Financial leadership of the company
  • 1.2 billion dollars money, cash equivalents and marketable securities from September 30, 2024expected to fund operations until at least 2028
• Darovasertib, a potential first-in-class Phase 2/3 PKC inhibitor program targeting metastatic uveal melanoma (MUM) and uveal melanoma (UM)
  • Median progression-free survival readings for a potential Phase 2/3 registration-enabling trial of the combination of darovasertib and crizotinib in first-line (1L) patients with HLA-A2-negative MUM targeted by the end of 2025, pending enrollment status and data maturity. Enrollment has exceeded more than 200 patients since January 6, 2025
  • Median overall survival of phase 2 1L MUM for the combination of darovasertib and crizotinib in approximately 38 patients with 1L MUM targeted in 2025.
  • Neoadjuvant UM Targeted Phase 2 Clinical Data Update for Darovasertib in More than 75 Patients and 2025 Regulatory Update.
  • The start of a Phase 3 trial to enable the registration of darovasertib in neoadjuvant UM is planned for the first half of 2025.
• IDE397, a potential first-in-class MAT2A inhibitor phase 2 program targeting solid tumors with MTAP deletion
  • Clinical Program Update(s) for the Phase 1/2 study of IDE397 in combination with Trodelvy ^® in MTAP-deletion urothelial carcinoma (UC) 2025
  • Goal (NYSE: ) to enable a clinical combination of wholly owned IDE397 + IDE892 (IDEAYA PRMT5) targeting MTAP deletion non-small cell lung cancer (NSCLC) in the second half of 2025
• IDE849 (SHR-4849), a potential first-in-class Phase 1 DLL3 TOP1i ADC targeting small cells Lung cancer (SCLC) and neuroendocrine tumors (NET)
  • Clinical program update(s) planned for 2025
  • Updated slides of the IDE849 clinical program were provided in the JPM 2025 corporate presentation, including the preclinical product profile, CT-scanned tumor size waterfall using RECIST 1.1, and SCLC patient case study
• IDE275 (GSK959), a potential first-in-class Werner Helicase Phase 1 program targeting MSI-high solid tumors
  • Targeting a medical conference presentation with GSK, highlighting IDE275’s differentiated best-in-class potential profile, in the first half of 2025.
• IDE161, a potential first-in-class PARG inhibitor program in Phase 1 targeting solid tumors
  • Targeting Phase 1 expansion of IDE161 in combination with KEYTRUDA ^® (pembrolizumab), Merck (NS:) anti-PD-1 therapy, in endometrial cancer with high MSI and MSS 2025.
  • Targeting the clinical combination of IDE161 with Topo-ADCs in 2025
• IDE705 (GSK101), a potential first-in-class phase 1 pol theta helicase inhibitor targeting homologous recombination deficient (HRD) solid tumors
  • Targeting phase 2 expansion in HRD solid tumors, enabling potential 10 million dollars milestone payment from GSK
• 3 IND filings targeted for 2025, representing IDEAYA’s 7^th8^thand 9^th potential clinical stage precision medicine oncology program targeting solid tumors
  • IDE892, a potential best-in-class MTA-cooperative PRMT5 inhibitor, mid-2025 Potential for combination with IDE397
  • IDE034, a potential first-in-class B7H3/PTK7 TOP1i bispecific ADC, in the second half of 2025. Combination potential with IDE161
  • IDE251, a potential first-in-class candidate for dual KAT6/7 inhibitor development, in the second half of 2025. Combination potential with multiple programs in preparation IDEAYA

IDEAYA’s updated JPM 2025 corporate presentation reflecting its 2025 corporate guidance is available on its website under Investor Relations: https://ir.ideayabio.com/.

An audio broadcast of the presentation and live Q&A will be available in the “Investors/Events” section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host. A replay of the webcast will be available 30 days after the live event.

About IDEAS Biosciences

IDEAYA is a precision medicine oncology company dedicated to the discovery and development of targeted therapies for patient populations selected using molecular diagnostics. IDEAYA’s approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select the patient population most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality “, which represents an emerging class of precision medicine targets.

Forward-looking statements

This press release contains forward-looking statements, including, but not limited to, statements regarding (i) participation in and/or presentation at certain investor relations events and (ii) corporate guidance for 2025 in regarding the extent to which IDEAYA’s existing cash, cash equivalents and marketable securities will fund its planned operations and (iii) program updates regarding the potential timing of various activities. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to IDEAYA’s business generally, see IDEAYA’s current and future filings with US Securities and Exchange Commissionincluding its Annual Report on Form 10-K filed on February 20, 2024.

Contact for investors and media
IDEAS BiosciencesAndres Ruiz DeletedSenior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com